Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
55
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Fulcrum Therapeutics Inc market cap is $283.38M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Fulcrum Therapeutics Inc 52 week high is $15.74 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Fulcrum Therapeutics Inc 52 week low is $2.83 as of November 20, 2026.
Fulcrum Therapeutics Inc stock price today is $3.69.
Fulcrum Therapeutics Inc stock price yesterday was $3.71.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Fulcrum Therapeutics Inc's P/E ratio is -3.56.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Fulcrum Therapeutics Inc P/B ratio is 0.9382.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Fulcrum Therapeutics Inc 50-day moving average is $3.73.